Skip to Content
MilliporeSigma
  • Subtype-specific binding peptides enhance the therapeutic efficacy of nanomedicine in the treatment of ovarian cancer.

Subtype-specific binding peptides enhance the therapeutic efficacy of nanomedicine in the treatment of ovarian cancer.

Cancer letters (2015-02-11)
Yao-An Shen, Chang-Sheng Liu, Yen-Hou Chang, Po-Hung Chen, Chun-Lin He, Han-Chung Wu, Chi-Mu Chuang
ABSTRACT

Currently, epithelial ovarian cancer is viewed as a heterogeneous disease with five major histological subtypes. Clear cell carcinoma represents a specific histological subtype of epithelial ovarian cancer that demonstrates more aggressive clinical behavior and drug resistance compared with other subtypes. Nevertheless, clear cell carcinoma is treated in the same manner as the other subtypes without any particular consideration to its unique clinical characteristics. To improve the therapeutic efficacy of the current liposomal doxorubicin approach for the treatment of clear cell carcinoma, we aimed to develop a novel peptide-conjugated liposomal doxorubicin to actively target this subtype. Two phage clones (OC-6 and OC-26) that specifically bound to clear cell carcinoma were isolated from a phage peptide display library after biopanning procedures. The peptide sequences were translated and aligned (OCSP-6 for OC-6, and OCSP-26 for OC-26, respectively). Peptide-conjugated nanoparticles demonstrated better tumor endocytosis and time-dependent gradual increase of intracellular drug uptake than non-targeting liposomal nanoparticles. Furthermore, peptide-conjugated liposomal doxorubicin better controlled tumors than did non-targeting liposomal doxorubicin. The current work may pave a new way for the development of drugs that target each subtype of epithelial ovarian cancer in the future.

MATERIALS
Product Number
Brand
Product Description

Supelco
Sodium hydroxide concentrate, 0.1 M NaOH in water (0.1N), Eluent concentrate for IC
Sigma-Aldrich
Sodium hydroxide solution, 0.01 M
Sigma-Aldrich
Sodium hydroxide solution, 0.1 M
Sigma-Aldrich
Sodium hydroxide solution, 4 M
Sigma-Aldrich
Sodium hydroxide solution, 6 M
Sigma-Aldrich
Sodium hydroxide solution, 0.05 M
Sigma-Aldrich
Sodium hydroxide solution, 7 M
Sigma-Aldrich
Sodium hydroxide solution, 1 M
Sigma-Aldrich
Sodium hydroxide, ultra dry, powder or crystals, 99.99% trace metals basis
Aucubin, primary reference standard
Sigma-Aldrich
o-Phenylenediamine dihydrochloride, peroxidase substrate
Sigma-Aldrich
Ethanolamine, liquid, BioReagent, suitable for cell culture, ≥98%
Sigma-Aldrich
Ethanolamine, ≥98%
Sigma-Aldrich
o-Phenylenediamine dihydrochloride, tablet, 3 mg substrate per tablet
Sigma-Aldrich
o-Phenylenediamine dihydrochloride, tablet, 60 mg substrate per tablet
Sigma-Aldrich
o-Phenylenediamine dihydrochloride, tablet, 10 mg substrate per tablet
Sigma-Aldrich
o-Phenylenediamine dihydrochloride, tablet, 5 mg substrate per tablet
Sigma-Aldrich
o-Phenylenediamine dihydrochloride, tablet, 4 mg substrate per tablet
Sigma-Aldrich
o-Phenylenediamine dihydrochloride, tablet, 15 mg substrate per tablet
Sigma-Aldrich
Sodium hydroxide solution, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
o-Phenylenediamine dihydrochloride, tablet, 5 mg substrate per tablet
Sigma-Aldrich
Propidium iodide, ≥94.0% (HPLC)
Sigma-Aldrich
o-Phenylenediamine dihydrochloride, tablet, 2 mg substrate per tablet
Sigma-Aldrich
o-Phenylenediamine dihydrochloride, tablet, 30 mg substrate per tablet
Sigma-Aldrich
o-Phenylenediamine dihydrochloride, tablet, 1 mg substrate per tablet
Sigma-Aldrich
Ethanolamine, ≥99%
Supelco
Sodium hydroxide solution, 49-51% in water, eluent for IC
Sigma-Aldrich
Sodium hydroxide solution, BioUltra, for molecular biology, 10 M in H2O
Sigma-Aldrich
Sodium hydroxide, BioUltra, for luminescence, ≥98.0% (T), pellets
Supelco
Calcium standard for AAS, analytical standard, 1.000 g/L Ca+2 in hydrochloric acid, traceable to BAM